ANDA 76184, held by Teva Pharms. Alendronate Sodium.
As of Nov 16, 2026, ANDA 76184 (Alendronate Sodium), held by Teva Pharms, was first approved by FDA on Feb 6, 2008, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2008 | Original application | Approved |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| May 1, 2012 | Supplement 5Labeling | Approved | None posted |
| Sep 10, 2009 | Supplement 4Labeling | Approved | None posted |
| Aug 4, 2008 | Supplement 1Labeling | Approved | None posted |
| Aug 4, 2008 | Supplement 2Manufacturing | Approved | None posted |
| Aug 4, 2008 | Supplement 3Labeling | Approved | None posted |
| Feb 6, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters